Up RNA

UpRNA is a biotechnology company dedicated to developing a new class of RNA-based medicines that up-regulate protein expression to treat serious diseases. The company's proprietary platform utilizes synthetic oligonucleotides to target regulatory elements, thereby increasing the production of specific proteins that are deficient in certain genetic conditions. UpRNA's approach addresses diseases caused by haploinsufficiency, where a single functional copy of a gene is insufficient to maintain health. Currently in the pre-clinical stage, the company is focusing its efforts on central nervous system disorders and rare genetic diseases. UpRNA was founded by leading experts in RNA biology and is supported by prominent life science venture capital firms. The technology represents a significant shift from traditional RNA therapies that typically focus on gene silencing or down-regulation.